Our company’s lead product is a first-in-class oral agent that results in increased production of protective regulatory T cells that secrete anti-inflammatory IL-10 at specific sites of inflammation. This orally-administered ZPS therapeutic is being developed as an entirely novel class of treatment for Multiple Sclerosis, Inflammatory Bowel Disease and other important immune mediated diseases. ZPS therapeutics were the first microbiome-derived therapeutic molecules to exhibit a direct immune-modulating effect, and are now the first microbiome-derived therapeutic molecules to be protected by issued composition-of-matter patents. In extensive publications, the novel mechanism of action for ZPS therapeutics has been extensively studied and described, and these molecules work by stimulating the induction of regulatory lymphocytes. As they are based on commensal-derived molecules that have evolved over millennia to co-exist and modulate the human immune system, we expect much greater safety for orally-administered ZPS therapeutics.